FE
37
-4
NWSA
43
-2
PAYX
54
-3
CHRW
45
-2
PFG
55
-4
DD
44
-2
TRV
34
-11
APD
65
16
DVA
67
-5
TGNA
35
-2
DE
46
-2
HCA
51
-6
HBI
73
5
VRTX
39
-2
AAPL
40
-6
DOV
59
-2
PNC
53
-2
QCOM
51
-4
CNP
60
-8
MA
55
-7
FE
37
-4
NWSA
43
-2
PAYX
54
-3
CHRW
45
-2
PFG
55
-4
DD
44
-2
TRV
34
-11
APD
65
16
DVA
67
-5
TGNA
35
-2
DE
46
-2
HCA
51
-6
HBI
73
5
VRTX
39
-2
AAPL
40
-6
DOV
59
-2
PNC
53
-2
QCOM
51
-4
CNP
60
-8
MA
55
-7
Financhill
Back

MoonLake Immunotherapeutics Stock Predictions

Why Over 21,997 Investors Are Flocking to This Opportunity

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
64

MLTX
MoonLake Immunotherapeutics

Last Price:
49.97
Seasonality Move:
13.55%

7 Day Trial

ALL ACCESS PASS

$ 7

Forget Bitcoin - This Is the Real Opportunity of 2024

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

MoonLake Immunotherapeutics Stock Forecast

  • Over the next 52 weeks, MoonLake Immunotherapeutics has on average historically risen by 200.4% based on the past 3 years of stock performance.
  • MoonLake Immunotherapeutics has risen higher in 1 of those 3 years over the subsequent 52-week period, corresponding to a historical accuracy of 33.33%
  • Is MoonLake Immunotherapeutics Stock Undervalued?
    The current MoonLake Immunotherapeutics [MLTX] share price is $51.79. The Score for MLTX is 64, which is 28% above its historic median score of 50, and infers lower risk than normal.
  • MLTX is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.

Will MoonLake Immunotherapeutics Stock Go Up Next Year?

  • Over the next 52 weeks, MoonLake Immunotherapeutics has on average historically risen by 200.4% based on the past 3 years of stock performance.

MoonLake Immunotherapeutics Stock Rating

Buy
64
MoonLake Immunotherapeutics (MLTX) is a Buy

Is MoonLake Immunotherapeutics overpriced?

  • MoonLake Immunotherapeutics has risen higher in 1 of those 3 years over the subsequent 52-week period, corresponding to a historical accuracy of 33.33%

MoonLake Immunotherapeutics Stock Price History

Is MLTX stock going to rise?

  • The current trend is moderately bearish and MLTX is experiencing selling pressure, which indicates risk of future bearish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
Switzerland
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
moonlaketx.com

52-Week Data

52-Week High:
64.98
52-Week Low:
35.11

Prediction Charts

Market Cap:
3.26B
Price in USD:
51.79
Volume:
283.6K
Beta:
1.27

Technical Analysis

SMA50:
48.16
SMA100:
45.30
SMA200:
48.31
52-Wk Change:
-14.28%

Stock Predictions

  • Is MoonLake Immunotherapeutics stock public?
    Yes, MoonLake Immunotherapeutics is a publicly traded company.
  • What is the MoonLake Immunotherapeutics stock quote today?
    The MoonLake Immunotherapeutics stock price is 51.79 USD today.
  • How to buy MoonLake Immunotherapeutics stock online?
    You can buy MoonLake Immunotherapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Sep-18 51.49 53.11 55.05 51.27
Sep-19 54.10 53.71 54.89 53.03
Sep-20 53.47 54.04 54.53 53.04
Sep-23 54.19 55.40 55.74 53.49
Sep-24 55.58 54.33 55.58 53.55
Sep-25 54.73 50.81 54.73 50.42
Sep-26 51.25 51.37 52.37 50.06
Sep-27 51.58 49.40 51.58 49.39
Sep-30 49.41 50.49 52.75 49.41
Oct-1 50.36 51.72 52.10 50.01
Oct-2 51.58 51.82 52.39 50.62
Oct-3 51.48 52.04 52.44 50.80
Oct-4 52.57 55.24 55.91 50.00
Oct-7 55.82 51.79 56.00 50.43

MoonLake Immunotherapeutics Earnings

MoonLake Immunotherapeutics Earnings Report: Per Share MoonLake Immunotherapeutics Earnings Q1 Q2 Q3 and Q4 last year and next year.

MoonLake Immunotherapeutics Forecast Revenue Growth

MoonLake Immunotherapeutics Stock Analysis: Historical quarterly revenues per share for MoonLake Immunotherapeutics and historical quarterly revenue growth:

  • Analysts estimate an earnings decrease this quarter of $0.21 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.61 per share, and a decrease next year of $0.76 per share.

* MoonLake Immunotherapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.